Article
Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Clinical drug investigation - 1 Aug 2016
Khatri Amit, Mensing Sven, Podsadecki Thomas, Awni Walid, Menon Rajeev, Dutta Sandeep
Abstract excerpt
BACKGROUND AND OBJECTIVES: The three-direct-acting antiviral (DAA) combination regimen of ombitasvir, paritaprevir (coadministered with ritonavir [paritaprevir/ritonavir], and dasabuvir (the 3D regimen) ± ribavirin for treatment of HCV genotype 1-infected patients demonstrated efficacy and safety in Phase II and Phase III clinical trials. The relationships between the steady-state exposure (area under the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
